Identification of Endotypes of Hospitalized COVID-19 Patients

Area of Science:

• * Infectious Diseases
• * Clinical Medicine
• * Immunology

Background:

• * Characterizing coronavirus disease 2019 (COVID-19) endotypes is crucial for understanding variable clinical presentations and treatment responses.
• * Previous research has identified COVID-19 risk factors, but specific endotypes remain largely undescribed.
• * Elucidating COVID-19 endotypes can refine patient stratification and therapeutic strategies.

Purpose of the Study:

• * To identify and characterize distinct endotypes among hospitalized patients diagnosed with COVID-19.
• * To provide a framework for understanding patient heterogeneity in COVID-19 severity and outcomes.

Main Methods:

• * Employed consensus clustering (ensemble method) utilizing patient age and admission laboratory values.
• * Analyzed data from 528 hospitalized COVID-19 patients at Columbia University Irving Medical Center (March 12–July 15, 2020).

Main Results:

• * Identified four unique COVID-19 endotypes, differentiated by laboratory values, demographics, outcomes, and treatments.
• * Endotypes 1 and 2 showed low intubation rates (1-6%) and mortality (1-6%), while endotypes 3 and 4 had high intubation rates (72-85%) and mortality (21-43%).
• * Endotype 1 exhibited low inflammatory, infectious, and coagulopathy markers; endotype 4 showed elevated levels of these markers. Endotypes 2 and 4 were associated with more comorbidities.

Conclusions:

• * Four distinct COVID-19 endotypes were identified in hospitalized patients, correlating with inflammatory and infectious markers, end-organ dysfunction, comorbidities, and clinical outcomes.
• * The study found that high comorbidity burden did not consistently associate with poorer outcome endotypes.
• * Further validation in diverse cohorts and investigation into endotype-specific treatment responses are warranted.